In this article, we will list the 5 Best Life Sciences Penny Stocks to Buy. Please visit 8 Best Life Sciences Penny Stocks to Buy if you’d like to see an extended list and how we came up with it.

5. Cytek Biosciences Inc. (NASDAQ:CTKB)

Cytek Biosciences Inc. (NASDAQ:CTKB) is one of the 8 Best Life Sciences Penny Stocks to Buy.

As of the April 8 closing, the consensus sentiment around Cytek Biosciences Inc. (NASDAQ:CTKB) remained moderately bullish. With 1 Buy rating and 1 Hold rating, the stock has a projected median 1-year price target of $6.25, resulting in an upside of almost 38%.

On April 4, the company shared updates around the Cytek Aurora CS system. This involved a new guide to simplify the procedure to determine the most effective drop charge configurations that can be applied to smaller samples. It also involves Horseradish Peroxidase assay, which can be used to enable researchers to maneuver key parameters for drop charge. The company aims to leverage users who work with small samples to enhance the reliability and accuracy of workflows.

In late February, Cytek Biosciences Inc. (NASDAQ:CTKB) rolled out its 2026 revenue guidance of $205 million to $212 million, assuming constant currency exchange rates and no significant change in tariffs. CFO William McCombe added that the range was made in consideration of the improved economic environment in EMEA and the U.S., combined with sustained growth in APAC instrument sales, as well as services and reagents.

The proportion of recurring revenue to revenue was expected to continue growing, driven by increased instrument installations. CFO William McCombe mentioned macroeconomic uncertainty, raw material costs, tariffs, and high operating expenses, with mention of increased material and tariff costs and manufacturing overhead related to duplicated expenses associated with relocating a plant abroad.

Cytek Biosciences Inc. (NASDAQ:CTKB) delivers cell analysis tools to support scientific developments in biomedical research and clinical applications. It provides an automated micro-sampling and sample loader system along with conventional flow and image-based flow cytometry. Its extensive portfolio includes flow cytometers, reagent cocktail preparation systems, Aurora and Northern Lights systems, and more.

4. Standard BioTools Inc. (NASDAQ:LAB)

Standard BioTools Inc. (NASDAQ:LAB) is one of the 8 Best Life Sciences Penny Stocks to Buy.

As of the April 8 close, Standard BioTools Inc. (NASDAQ:LAB) had a neutral consensus sentiment. The stock received 2 Hold ratings from analysts, with a projected median 1-year price target of $1.35. This yields an impressive upside potential of more than 52%.

On March 16, Ark Invest revealed changes to some of its existing holdings, including reductions across some of the smaller genomics stocks. The investment management firm exited some portion of its Standard BioTools Inc. (NASDAQ:LAB) holdings.

In late February, Michael Egholm, President & CEO, reflected on the company’s fourth quarter results. He described the passing year as a good one for the company, highlighting that the company was able to beat expectations through efficient processes being followed across the organization.

Egholm also noted that the company has been able to remain focused on efficiency due to the fact that it successfully implemented roughly $40 million worth of cost synergies during the year.

Standard BioTools Inc. (NASDAQ:LAB) is engaged in the production and sales of a variety of consumables, instruments, and services to help scientists and biomedical researchers create medical treatments. The company offers a technological platform that includes CyTOF, Hyperion, and Biomark X9. These platforms are used for advanced molecular and proteomics analysis.

3. Pacific Biosciences of California Inc. (NASDAQ:PACB)

Pacific Biosciences of California Inc. (NASDAQ:PACB) is one of the 8 Best Life Sciences Penny Stocks to Buy.

On March 18, Pacific Biosciences of California Inc. (NASDAQ:PACB) revealed that Basecamp Research, a novel artificial intelligence research lab dedicated to the development of therapeutics, has chosen PacBio’s highly accurate (HiFi) sequencing on the company’s Revio platform. This will be utilized for the delivery of large-scale environmental and associated host metagenomic datasets to enable the Trillion Gene Atlas program. This is a pioneering scientific endeavor that seeks to generate and model biological data at the trillion-gene level.

This collaboration is expected to generate around 100,000 samples that will be extensively sequenced to produce the largest and most diverse metagenomics database compiled to date, covering more than 31 countries on five different continents. With advancements being made in AI modeling to facilitate biological designs, the performance of AI models largely depends on the nature of the datasets used in the training process.

On March 6, Barclays lowered its price target on Pacific Biosciences of California, Inc. (NASDAQ:PACB) from $2 to $1.5. The firm also downgraded the rating from Equal Weight to Underweight. This downward revision comes due to the expectations of a difficult market environment in the immediate future.

Amid the competitive launches across the sequencing space, the firm has anticipated a potential pause in the overall demand. Consequently, in the first half of 2026, the company might see a temporary drop in consumable sales, due to clients purposefully postponing their research projects in preparation for the launch of the SPRQ NX platform.

Pacific Biosciences of California Inc. (NASDAQ:PACB) is involved in designing and producing sequencing systems to solve genetically complex problems around the globe. It serves genome centers, public health labs, hospitals, and more by selling them technologies which include single-molecule real-time (SMRT) technology, SMRTbell and Revio, Vega, and Sequel instruments.

2. AbCellera Biologics Inc. (NASDAQ:ABCL)

AbCellera Biologics Inc. (NASDAQ:ABCL) is one of the 8 Best Life Sciences Penny Stocks to Buy.

On March 23, AbCellera Biologics Inc. (NASDAQ:ABCL) presented at the 2026 KeyBanc Capital Markets Healthcare Virtual Forum, with Senior Director of Strategic Finance and Investor Relations Martin Hogan covering the company’s drug discovery platform and pipeline development. Hogan provided an interesting insight into the story of about 13 years, which began with investing in technologies for almost a decade for developing capabilities from target nominations through manufacturing of the drug product, all related to antibodies as therapeutic agents.

The speaker argued that the differentiated technology approach taken in drug discovery, along with all the investments made since, in addition to the more than 100 programs that the company was involved in discovering drugs, resulted in establishing the capability of tackling the hardest targets accessible using antibody-based therapies. Not only does this create a downstream stake in programs conducted by the company for their partners, but it also creates a portfolio of internal programs. Recently, the company progressed one of its drugs into Phase II of its clinical study, effectively becoming an integrated mid- to late-stage biotech firm.

According to Hogan, there were four key factors considered during the assessment of each program’s feasibility: derisked science, high unmet medical need and commercial viability, competitive advantage, and a sound path for developing the candidate drugs.

AbCellera Biologics Inc. (NASDAQ:ABCL) is involved in the research and development of antibody-based medications to address unmet healthcare needs in the U.S. It has two medicine candidates: ABCL635, which is in Phase 2 of clinical trials, and ABCL575, which is in Phase 1. Additionally, it has partnership agreements with firms, including those with Eli Lilly and Company and AbbVie Inc.

1. OmniAb Inc. (NASDAQ:OABI)

OmniAb Inc. (NASDAQ:OABI) is one of the 8 Best Life Sciences Penny Stocks to Buy.

On March 5, guidance for 2026 revenues for OmniAb Inc. (NASDAQ:OABI) was estimated at $25 million to $30 million, driven by growth in the partner pipeline and launches of the OmniUltra and xPloration products. According to Matthew Foehr, CEO of OmniAb Inc., 2026 will be characterized by the build-up of momentum with special focus on partnering and programs.

Foehr also emphasized launching OmniUltra at the Antibody Engineering Conference as the first and only transgenic chicken platform to express ultra-long CDRH3 on a human antibody framework. According to Foehr, OmniUltra would act as a catalyst for growth through partnerships and revenue growth, while xPloration was aimed at bringing single B-cell screening at a high throughput directly to partners’ laboratories, with the potential of adding to the overall growth.

Considering the remarks given by Kurt Gustafson, the Chief Financial Officer, the projected expenses for 2026 would range from $80 million to $85 million as the company becomes more efficient with its operations. Cash operating expenses are expected to range between $50 million and $55 million, whereas the cash balance by the end of the period is projected between $30 million and $35 million.

OmniAb Inc. (NASDAQ:OABI) provides licenses to pharmaceutical and biotech companies for discovery research technology around various parts of the world. To find the best antibodies and other target-binding proteins for partners’ drug development efforts, the company’s technology platform creates and screens diverse antibody repertoires. Animal-based technologies are also offered by the company.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 12 Oversold Financial Stocks to Invest in According to Hedge Funds.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.